Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Eight Human Papillomavirus Types Cause Most Cervical Cancers

By LabMedica International staff writers
Posted on 09 Nov 2010
Eight human papillomavirus (HPV) types cause more than 90% of all cervical cancers worldwide, and three types cause 94% of cervical adenocarcinomas.

Polymerase chain reaction (PCR) and DNA testing were used to identify the HPV genotypes present in tissue samples collected from a large number of patients who had invasive cervical cancer. More...


A massive multinational cervical cancer study was carried out at the Catalan Institute of Oncology (Barcelona, Spain) where paraffin-embedded samples of histologically confirmed cases of invasive cervical cancer were tested. The samples were collected from 38 countries in Europe, North America, central South America, Africa, Asia, and Oceania. HPV detection was done by use of PCR with short PCR fragment (SPF-10) broad-spectrum primers followed by DNA enzyme immunoassay and genotyping with a reverse-hybridization line probe assay. Sequence analysis was done to characterize HPV-positive samples with unknown HPV types. Data analyses included algorithms of multiple infections to estimate type-specific relative contributions.

The retrospective cross-sectional study collected samples from 10,575 cases of invasive cervical cancer diagnosed between 1949 and 2009 and 8,977 (85%) of these were positive for HPV DNA. The eight most common HPV types identified were, in descending order of frequency: 16, 18, 45, 33, 31, 52, 58, and 35. HPV types 16, 18, and 45 were detected in 443 of 470 cases (94%) of cervical adenocarcinomas. Unknown HPV types that were identified with sequence analysis were 26, 30, 61, 67, 69, 82, and 91 in 103 (1%) of 8,977 cases of invasive cervical cancer. Women with invasive cervical cancers related to HPV types 16, 18, or 45 presented at a younger mean age than did those with other HPV types. The results suggest that type-specific high-risk HPV-DNA-based screening tests and protocols should focus on HPV types 16, 18, and 45.

Silvia de Sanjose, M.D., the lead author said, "HPV types 16, 18, 31, 33, 34, 45, 52, and 58 should be given priority when the cross-protective effects of current vaccines are assessed and for formulation of recommendations for the use of second-generation polyvalent HPV vaccines." The study was published October 15 2010, in the journal Lancet Oncology.

Related Links:
Catalan Institute of Oncology



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Manual Pipetting Aid
Pipette Controllers macro
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.